Open an account

Novo Nordisk A/S

NVO · OMX

$39.05−$0.38 (−0.96%)TodayMarket closed ·
Prev close $39.43

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Employees
68,794
Headquarters
Bagsvaerd
Listed
May 17, 1974
Sector
Health Care
Industry
Pharmaceuticals
Website
novonordisk.com

NVO key statistics

Market cap
1.17T
Price-earnings ratio
9.88
Dividend yield
4.43%
Average volume
11.83M
Volume
9.19M
Open price
$39.15
High today
$39.29
Low today
$38.75
52 Week high
$64.16
52 Week low
$35.12

Novo Nordisk A/S (NVO) at a glance

Novo Nordisk A/S (NVO) last traded at $39.05, with a market cap of 1.17T, a price-to-earnings ratio of 9.88 and a dividend yield of 4.43%.

Today the stock has traded between $38.75 and $39.29. The current price is 0.8% above the day's low and 0.6% below its high.

Volume so far is 9.19M shares, below the average of 11.83M shares a day.

Over the past year Novo Nordisk A/S has ranged from $35.12 to $64.16, and now sits 14% of the way up that range.

Novo Nordisk A/S met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $4.75 per share against an estimate of $5.03.

The average analyst price target is $46.38, 18.8% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

13%of 8 analyst ratings say Buy
  • Buy12.5%
  • Hold62.5%
  • Sell25.0%
Price target · 31 analystsAvg $46.38
Low
$30.60
Now
$39.05
High
$69.74

NVO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 7.3% on average.

  1. Q3 FY24: reported $6.12 per share against an estimate of $6.08
  2. Q4 FY24: reported $6.34 per share against an estimate of $5.90
  3. Q1 FY25: reported $6.53 per share against an estimate of $6.28
  4. Q2 FY25: reported $5.96 per share against an estimate of $6.03
  5. Q3 FY25: reported $4.50 per share against an estimate of $4.84
  6. Q4 FY25: reported $6.04 per share against an estimate of $5.96
  7. Q1 FY26: reported $6.63 per share against an estimate of $5.39
  8. Q2 FY26: reported $4.75 per share against an estimate of $5.03

NVO news

  • Novo Nordisk's Awiqli Receives FDA Approval As The First And Only Once-Weekly Insulin For Children 10 Years Of Age And Older With Type 2 Diabetes

  • Tanya Rawat

    More Americans Now Take GLP-1 Drugs for Weight Loss Than Diabetes as Food, Alcohol and Apparel Habits Shift, Survey Finds

  • Akanksha Bakshi

    Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research

  • Mohd Haider

    Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’

  • Vandana Singh

    FDA Delays Regulatory Decision On Novo Nordisk Hemophilia Drug

  • Mohd Haider

    Anthropic Commits $100 Million Behind AI Talent Push, Plans to Train 10,000 Engineers by 2027 as IPO Looms

  • Novo Provides Update On The Denecimig Biologics License Application In The US; The FDA Has Informed Novo That The BLA Review Of Denecimig For The Treatment Of Haemophilia A Is Still Ongoing; The FDA Has Not Communicated A New Timeline For Regulatory Action On The BLA

  • Vandana Singh

    Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.